FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2737036730> ?p ?o ?g. }

• W2737036730 abstract "Psoriatic arthritis (PsA) is a chronic inflammatory arthritis which impacts significantly on the quality of life and work capacity of affected individuals. Recent evidence has shown that early control of inflammation in PsA leads to improved long-term outcomes. It is postulated that prompt intervention after diagnosis using a remission-induction treatment strategy will lead to improved outcomes and optimal disease control of PsA. The aim of the present study was to compare the clinical efficacy of a treatment strategy in newly diagnosed, treatment naïve PsA subjects, using the combination of golimumab (GOL), methotrexate (MTX) and steroids versus standard care (MTX monotherapy plus steroids). GOLMePsA is an investigator initiated, phase IIIb, single-centre, randomised, double-blind, placebo-controlled, two-armed, parallel-group, imaging-supplemented study. Eighty-eight PsA patients, diagnosed within 24 months prior to screening and treatment naïve, will be randomised at baseline to receive: (arm 1) the combination of intramuscular/intra-articular prednisolone, MTX and GOL or (arm 2) the combination of intramuscular/intra-articular prednisolone, MTX and placebo for 24 weeks (interventional period). Primary outcome measure is clinical improvement (at least 1 unit difference) in the Psoriatic ArthritiS Disease Activity Score (PASDAS) composite index. Reflecting a “step down” therapeutic approach, all participants successfully completing the interventional period will be followed up for a further 28 weeks. During this observational period, stable maintenance MTX monotherapy will continue for both arms, unless in case of intolerance or PsA relapse. In the latter case, additional treatment will be provided. Overall, the GOLMePsA study length is planned to be 52 weeks. The hypothesis underlining this study is that very early treatment with first-line GOL reduces disease activity in PsA, in comparison to conventional therapy. EudraCT 2013–004122-28 . 24/09/2013." @default.
• W2737036730 created "2017-07-31" @default.
• W2737036730 creator A5009624195 @default.
• W2737036730 creator A5018678002 @default.
• W2737036730 creator A5034487717 @default.
• W2737036730 creator A5051239558 @default.
• W2737036730 creator A5053315948 @default.
• W2737036730 creator A5074519726 @default.
• W2737036730 creator A5085522760 @default.
• W2737036730 date "2017-07-18" @default.
• W2737036730 modified "2023-09-27" @default.
• W2737036730 title "The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes" @default.
• W2737036730 cites W1522722546 @default.
• W2737036730 cites W1533838190 @default.
• W2737036730 cites W1535687499 @default.
• W2737036730 cites W1966756501 @default.
• W2737036730 cites W1967769016 @default.
• W2737036730 cites W1968958817 @default.
• W2737036730 cites W1976217778 @default.
• W2737036730 cites W1983134858 @default.
• W2737036730 cites W1985004174 @default.
• W2737036730 cites W1992885607 @default.
• W2737036730 cites W1996389186 @default.
• W2737036730 cites W2003717175 @default.
• W2737036730 cites W2035612894 @default.
• W2737036730 cites W2040865134 @default.
• W2737036730 cites W2045317929 @default.
• W2737036730 cites W2054242247 @default.
• W2737036730 cites W2067204410 @default.
• W2737036730 cites W2067327580 @default.
• W2737036730 cites W2068573602 @default.
• W2737036730 cites W2083180635 @default.
• W2737036730 cites W2113717019 @default.
• W2737036730 cites W2122980756 @default.
• W2737036730 cites W2126477323 @default.
• W2737036730 cites W2128759000 @default.
• W2737036730 cites W2128840310 @default.
• W2737036730 cites W2133696182 @default.
• W2737036730 cites W2149168537 @default.
• W2737036730 cites W2150454702 @default.
• W2737036730 cites W2151546682 @default.
• W2737036730 cites W2154464235 @default.
• W2737036730 cites W2159106700 @default.
• W2737036730 cites W2167948681 @default.
• W2737036730 cites W2183003717 @default.
• W2737036730 cites W2208044338 @default.
• W2737036730 cites W2214981256 @default.
• W2737036730 cites W2220479222 @default.
• W2737036730 cites W2549385305 @default.
• W2737036730 cites W4211250344 @default.
• W2737036730 doi "https://doi.org/10.1186/s12891-017-1659-1" @default.
• W2737036730 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5516354" @default.
• W2737036730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28720139" @default.
• W2737036730 hasPublicationYear "2017" @default.
• W2737036730 type Work @default.
• W2737036730 sameAs 2737036730 @default.
• W2737036730 citedByCount "8" @default.
• W2737036730 countsByYear W27370367302017 @default.
• W2737036730 countsByYear W27370367302019 @default.
• W2737036730 countsByYear W27370367302020 @default.
• W2737036730 countsByYear W27370367302021 @default.
• W2737036730 countsByYear W27370367302022 @default.
• W2737036730 crossrefType "journal-article" @default.
• W2737036730 hasAuthorship W2737036730A5009624195 @default.
• W2737036730 hasAuthorship W2737036730A5018678002 @default.
• W2737036730 hasAuthorship W2737036730A5034487717 @default.
• W2737036730 hasAuthorship W2737036730A5051239558 @default.
• W2737036730 hasAuthorship W2737036730A5053315948 @default.
• W2737036730 hasAuthorship W2737036730A5074519726 @default.
• W2737036730 hasAuthorship W2737036730A5085522760 @default.
• W2737036730 hasBestOaLocation W27370367301 @default.
• W2737036730 hasConcept C126322002 @default.
• W2737036730 hasConcept C141071460 @default.
• W2737036730 hasConcept C142724271 @default.
• W2737036730 hasConcept C168563851 @default.
• W2737036730 hasConcept C198451711 @default.
• W2737036730 hasConcept C204787440 @default.
• W2737036730 hasConcept C27081682 @default.
• W2737036730 hasConcept C2776260265 @default.
• W2737036730 hasConcept C2776715498 @default.
• W2737036730 hasConcept C2777077863 @default.
• W2737036730 hasConcept C2777226972 @default.
• W2737036730 hasConcept C2777575956 @default.
• W2737036730 hasConcept C2781059491 @default.
• W2737036730 hasConcept C2781290027 @default.
• W2737036730 hasConcept C535046627 @default.
• W2737036730 hasConcept C71924100 @default.
• W2737036730 hasConceptScore W2737036730C126322002 @default.
• W2737036730 hasConceptScore W2737036730C141071460 @default.
• W2737036730 hasConceptScore W2737036730C142724271 @default.
• W2737036730 hasConceptScore W2737036730C168563851 @default.
• W2737036730 hasConceptScore W2737036730C198451711 @default.
• W2737036730 hasConceptScore W2737036730C204787440 @default.
• W2737036730 hasConceptScore W2737036730C27081682 @default.
• W2737036730 hasConceptScore W2737036730C2776260265 @default.
• W2737036730 hasConceptScore W2737036730C2776715498 @default.
• W2737036730 hasConceptScore W2737036730C2777077863 @default.
• W2737036730 hasConceptScore W2737036730C2777226972 @default.
• W2737036730 hasConceptScore W2737036730C2777575956 @default.
• W2737036730 hasConceptScore W2737036730C2781059491 @default.

• next